Regulus renews Sanofi microRNA pact to focus on orphan, cancer treatments

California microRNA specialist Regulus Therapeutics ($RGLS) renewed an almost-four-year-old partnership with Sanofi ($SNY) to help develop its RNA programs further for orphan and oncology purposes, collecting a $10 million equity investment in the process. Of particular interest to Sanofi is Regulus' microRNA-21 candidate for the orphan kidney-affecting Alport syndrome and a proof-of-concept cancer treatment. Back in 2010, Sanofi hooked up with Regulus--a spinoff of Alnylam ($ALNY) and Isis ($ISIS)--for up to $750 million. The two companies are using the discovery and delivery techniques developed by Alnylam and Isis to, they hope, finally make RNA drugs effective. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…